Cargando…

Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test

(1) Objective: To investigate the factors that affect rates of neutralizing antibody production and duration after vaccination using the newly developed SARS-CoV-2 POCT. (2) Methods: The production of immunoglobulin and neutralizing antibody in clinical subjects who completed various vaccines was an...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Hyeon Woo, Shin, Jae hang, Shin, Shang Cheol, Lee, Hwa Jung, So, Kyung Soon, Lee, So Young, Jun, Jae Woo, Seo, Jeong Ku, Lee, Hwa Seop, Lee, Suk Young, Kim, Seung Hyun, Kim, Sun Jong, Kim, Kyoung-Chol, Ryu, Gyu Ha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406444/
https://www.ncbi.nlm.nih.gov/pubmed/36010274
http://dx.doi.org/10.3390/diagnostics12081924
_version_ 1784774122444685312
author Shim, Hyeon Woo
Shin, Jae hang
Shin, Shang Cheol
Lee, Hwa Jung
So, Kyung Soon
Lee, So Young
Jun, Jae Woo
Seo, Jeong Ku
Lee, Hwa Seop
Lee, Suk Young
Kim, Seung Hyun
Kim, Sun Jong
Kim, Kyoung-Chol
Ryu, Gyu Ha
author_facet Shim, Hyeon Woo
Shin, Jae hang
Shin, Shang Cheol
Lee, Hwa Jung
So, Kyung Soon
Lee, So Young
Jun, Jae Woo
Seo, Jeong Ku
Lee, Hwa Seop
Lee, Suk Young
Kim, Seung Hyun
Kim, Sun Jong
Kim, Kyoung-Chol
Ryu, Gyu Ha
author_sort Shim, Hyeon Woo
collection PubMed
description (1) Objective: To investigate the factors that affect rates of neutralizing antibody production and duration after vaccination using the newly developed SARS-CoV-2 POCT. (2) Methods: The production of immunoglobulin and neutralizing antibody in clinical subjects who completed various vaccines was analyzed using the POCT, the semi-quantitative was interpreted by measurement application, and the quantified neutralizing antibody titers were using the ELISA. (3) Results: According to the clinical performance analysis of the POCT, the clinical sensitivity and the specificity were 96.8% (90/93) and 97.7% (167/171), respectively, for the S1 RBD IgG antibody. The clinical sensitivity was 92.22% (83/90), and the clinical specificity was 100.00% (174/174) for neutralizing antibodies. Factors influencing antibody production were analyzed using the whole blood of the five types of second-completed vaccinators (N = 736, 20–80 years old). General and neutralizing antibody and showed significant differences in age (p < 0.0001), vaccine type (p < 0.0001), inoculation interval (p < 0.0001), pain score (p < 0.0001), diabetes (p < 0.0001), and hypertension (p = 0.002). The gender (p = 0.021) and chronic fatigue (p = 0.02) did not show the significance. (4) Conclusions: An acquisition of immunoglobulin and neutralizing antibody varies according to vaccine type, age, days after vaccination, pain degree after vaccination, and underlying diseases. The POCT used in this study will be utilized for clinical recommendations such as deciding whether to receive additional vaccines through the immediate rapid determination of neutralizing antibody generation in the clinical site.
format Online
Article
Text
id pubmed-9406444
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94064442022-08-26 Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test Shim, Hyeon Woo Shin, Jae hang Shin, Shang Cheol Lee, Hwa Jung So, Kyung Soon Lee, So Young Jun, Jae Woo Seo, Jeong Ku Lee, Hwa Seop Lee, Suk Young Kim, Seung Hyun Kim, Sun Jong Kim, Kyoung-Chol Ryu, Gyu Ha Diagnostics (Basel) Article (1) Objective: To investigate the factors that affect rates of neutralizing antibody production and duration after vaccination using the newly developed SARS-CoV-2 POCT. (2) Methods: The production of immunoglobulin and neutralizing antibody in clinical subjects who completed various vaccines was analyzed using the POCT, the semi-quantitative was interpreted by measurement application, and the quantified neutralizing antibody titers were using the ELISA. (3) Results: According to the clinical performance analysis of the POCT, the clinical sensitivity and the specificity were 96.8% (90/93) and 97.7% (167/171), respectively, for the S1 RBD IgG antibody. The clinical sensitivity was 92.22% (83/90), and the clinical specificity was 100.00% (174/174) for neutralizing antibodies. Factors influencing antibody production were analyzed using the whole blood of the five types of second-completed vaccinators (N = 736, 20–80 years old). General and neutralizing antibody and showed significant differences in age (p < 0.0001), vaccine type (p < 0.0001), inoculation interval (p < 0.0001), pain score (p < 0.0001), diabetes (p < 0.0001), and hypertension (p = 0.002). The gender (p = 0.021) and chronic fatigue (p = 0.02) did not show the significance. (4) Conclusions: An acquisition of immunoglobulin and neutralizing antibody varies according to vaccine type, age, days after vaccination, pain degree after vaccination, and underlying diseases. The POCT used in this study will be utilized for clinical recommendations such as deciding whether to receive additional vaccines through the immediate rapid determination of neutralizing antibody generation in the clinical site. MDPI 2022-08-09 /pmc/articles/PMC9406444/ /pubmed/36010274 http://dx.doi.org/10.3390/diagnostics12081924 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shim, Hyeon Woo
Shin, Jae hang
Shin, Shang Cheol
Lee, Hwa Jung
So, Kyung Soon
Lee, So Young
Jun, Jae Woo
Seo, Jeong Ku
Lee, Hwa Seop
Lee, Suk Young
Kim, Seung Hyun
Kim, Sun Jong
Kim, Kyoung-Chol
Ryu, Gyu Ha
Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test
title Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test
title_full Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test
title_fullStr Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test
title_full_unstemmed Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test
title_short Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test
title_sort analysis of factors affecting neutralizing antibody production after covid-19 vaccination using newly developed rapid point-of-care test
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406444/
https://www.ncbi.nlm.nih.gov/pubmed/36010274
http://dx.doi.org/10.3390/diagnostics12081924
work_keys_str_mv AT shimhyeonwoo analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT shinjaehang analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT shinshangcheol analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT leehwajung analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT sokyungsoon analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT leesoyoung analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT junjaewoo analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT seojeongku analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT leehwaseop analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT leesukyoung analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT kimseunghyun analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT kimsunjong analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT kimkyoungchol analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest
AT ryugyuha analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest